These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16841480)

  • 1. [Dopamine receptors agonists (mirapex) in the treatment of Parkinson's disease].
    Fedorova NV; Chigir' IP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(6):26-33. PubMed ID: 16841480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of the dopamine receptor agonist Mirapex in the treatment of Parkinson's disease.
    Fedorova NV; Chigir' IP
    Neurosci Behav Physiol; 2007 Jul; 37(6):539-46. PubMed ID: 17657423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mirapex (pramipexole) in the treatment of non-motor disturbances in Parkinson's disease].
    Nodel' MR; Iakhno NN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(5):32-8. PubMed ID: 18577955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of dopamine agonist pramipexole (mirapex) on tremor, affective disorders and quality of life in patients with Parkinson's disease].
    Levin OS; Boĭko AN; Nesterova OS; Otcheskaia OV; Zhuravleva EIu; Artemova IIu; Khozova AA; Ismailov AM; Lisenker LN; Vdovichenko TV; Rotor LD; Ganzhula PA; Ivanov AK
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(2):39-44. PubMed ID: 20436448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [7-year experience in usage of mirapex in patients with different forms of primary parkinsonism].
    Illarioshkin SN; Ivanova-Smolenskaia IA; Zagorovskaia TB; Karabanov AV; Poleshchuk VV; Markova ED; Karpova EA; Polevaia EV; Bagyeva GKh; Timerbaeva SL; Nurmanova ShA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(11):26-32. PubMed ID: 17180757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Influence of dopamine agonist pramipexole (mirapex) on tremor, cognitive and affective impairment in patients with Parkinson's disease].
    Levin OS; Nesterova OS; Otcheskaia OV; Zhuravleva EIu; Artemova IIu; Khozova AA; Ismailov AM; Lisenker LN; Vdovichenko TV; Rotor LD; Ganzula PA; Ivanov AK; Boĭko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(8):36-41. PubMed ID: 19738567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
    Litvinenko IV; Odinak MM; Mogil'naia VI; Sologub OS; Sakharovskaia AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(1):51-4. PubMed ID: 19156087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A comparative study of efficacy of dopamine receptors agonists and catechol-O-methyltransferase in the treatment of late stages of Parkinson's disease].
    Krivonos OV; Fedorova NV; Chigir' IP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(1):24-30. PubMed ID: 14870689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of two different dopamine agonists in the management of Parkinson's disease.
    Stocchi F; Berardelli A; Vacca L; Thomas A; De Pandis MF; Modugno N; Valente M; Ruggieri S
    Neurol Sci; 2002 Sep; 23 Suppl 2():S115-6. PubMed ID: 12548370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
    Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
    Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of controlled-release levodopa on the microstructure of sleep in Parkinson's disease.
    Wailke S; Herzog J; Witt K; Deuschl G; Volkmann J
    Eur J Neurol; 2011 Apr; 18(4):590-6. PubMed ID: 20849470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Parkinson's disease in the advanced stage.
    Ossig C; Reichmann H
    J Neural Transm (Vienna); 2013 Apr; 120(4):523-9. PubMed ID: 23474822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
    Dooley M; Markham A
    Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkinson's disease patients cannot get their dopamine replacement: the 8-Sinemet limit.
    Okun MS
    Mov Disord; 2012 Mar; 27(3):461-2. PubMed ID: 22162080
    [No Abstract]   [Full Text] [Related]  

  • 16. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.
    Marras C; Lang A; Krahn M; Tomlinson G; Naglie G;
    Mov Disord; 2004 Jan; 19(1):22-8. PubMed ID: 14743356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Influence of levodopa, stalevo on dyskinesia in Parkinson's disease: STRIDE-PD study].
    Liashchenko EA; Skripkina NA; Levin OS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(7 Pt 2):62-8. PubMed ID: 23994933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
    Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
    Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
    Ries V; Selzer R; Eichhorn T; Oertel WH; Eggert K;
    Clin Neuropharmacol; 2010 May; 33(3):142-50. PubMed ID: 20502133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-effect estimation of dopamine agonist (mirapex) application in patients with Parkinson's disease].
    Gekht AB; Belousov IuB; Chikina ES; Serkin GV; Belousov DIu; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(10):26-33. PubMed ID: 15553375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.